Astal Laboratories Ltd

Astal Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Astal Laboratories Ltd

₹ 81.8 2.53%
15 May - close price
astallabs.com BSE: 512600
About

Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).[1]

Key Points

Business Update[1]
Astal Laboratories Limited (formerly Macro International Limited) was taken over in 2022 under SEBI takeover regulations, following which its objects were changed to manufacturing and sale of pharmaceutical intermediates and bulk drugs. The name was subsequently changed to Astal Laboratories Limited in May 2024.

Website BSE
  • Market Cap ₹ 345 Cr.
  • Current Price ₹ 81.8
  • High / Low ₹ 103 / 60.4
  • Stock P/E 35.3
  • Book Value ₹ 40.5
  • Dividend Yield 0.00 %
  • ROCE 34.8 %
  • ROE 30.1 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 213% CAGR over last 5 years
  • Debtor days have improved from 246 to 157 days.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -13.5%
  • Promoter holding is low: 4.70%
  • Company has high debtors of 157 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
0.00 3.43 1.36 12.25 8.41 12.25 13.15 13.16 14.46 23.47 25.33 37.52 52.24
0.09 3.40 1.36 11.67 7.92 11.67 10.77 10.27 11.14 19.29 22.18 33.65 48.69
Operating Profit -0.09 0.03 0.00 0.58 0.49 0.58 2.38 2.89 3.32 4.18 3.15 3.87 3.55
OPM % 0.87% 0.00% 4.73% 5.83% 4.73% 18.10% 21.96% 22.96% 17.81% 12.44% 10.31% 6.80%
0.00 0.09 0.01 0.00 0.00 0.00 0.03 0.00 0.06 0.04 0.06 0.03 0.04
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.09 0.28 0.27 0.30 0.31 0.33
Depreciation 0.00 0.00 0.00 0.02 0.01 0.02 0.01 0.03 0.08 0.10 0.12 0.12 0.12
Profit before tax -0.09 0.12 0.01 0.56 0.48 0.56 2.34 2.77 3.02 3.85 2.79 3.47 3.14
Tax % 0.00% 16.67% 0.00% 0.00% 0.00% 0.00% 27.78% 27.80% 17.55% 28.57% 25.45% 25.36% 24.52%
-0.09 0.10 0.01 0.56 0.49 0.56 1.69 2.00 2.49 2.74 2.09 2.58 2.36
EPS in Rs -0.23 0.25 0.03 1.41 1.00 0.57 1.72 2.03 2.53 2.79 2.13 2.40 2.19
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
0 0 0 0 0 0 0 0 0 3 24 64 139
0 0 0 0 0 0 0 0 0 4 23 51 124
Operating Profit -0 -0 -0 -0 -0 -0 -0 0 -0 -0 1 13 15
OPM % 10% -4% 5% 20% 11%
0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 1 1
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit before tax 0 0 0 0 0 -0 -0 0 -0 0 1 12 13
Tax % 25% -260% 50% 0% 12% 0% 0% 67% 28% 25%
0 0 0 0 -0 -0 -0 0 -0 0 1 9 10
EPS in Rs 0.23 0.45 0.03 0.03 -0.03 -0.20 -0.08 0.03 -0.05 0.05 0.79 9.08 9.51
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 161%
Compounded Profit Growth
10 Years: 48%
5 Years: 213%
3 Years: 665%
TTM: 45%
Stock Price CAGR
10 Years: %
5 Years: 56%
3 Years: 36%
1 Year: -2%
Return on Equity
10 Years: 11%
5 Years: 16%
3 Years: 20%
Last Year: 30%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 4 4 4 4 4 4 4 4 4 4 10 10 11
Reserves 1 1 1 1 1 1 1 1 1 1 13 26 33
0 0 0 0 0 0 0 0 0 0 0 13 13
0 0 0 0 0 0 0 0 0 5 13 14 44
Total Liabilities 5 5 5 5 5 5 5 5 5 10 37 63 101
0 0 0 0 0 0 0 0 0 0 1 11 11
CWIP 0 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
5 5 5 5 5 5 5 5 5 10 36 52 89
Total Assets 5 5 5 5 5 5 5 5 5 10 37 63 101

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-1 -0 -0 -0 -0 -0 -0 -0 -0 -1 -6 -13
1 0 0 0 0 0 0 0 0 2 -6 -8
0 0 0 0 0 0 0 0 0 0 18 3
Net Cash Flow 0 -0 0 0 0 0 0 0 -0 0 6 -17
Free Cash Flow -1 -0 -0 -0 -0 -0 -0 -0 -0 -1 -11 -18
CFO/OP 371% 170% 81% 104% 100% 81% 95% -950% 125% 1,021% -496% -96%

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 0 337 244 157
Inventory Days 0 18 112
Days Payable 197 82
Cash Conversion Cycle 0 337 65 187
Working Capital Days -73 138 118 97
ROCE % 2% 1% 1% 0% 0% -2% -1% 0% 0% 1% 8% 35%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Revenue from Interest Income (Financial/Lending Business phase)
₹ Lacs

Log in to view insights

Please log in to see hidden values.

Login
Number of Owned Pharmaceutical Plants
Number
Number of Permanent Employees
Number
Reliance on Third-Party Manufacturing
Binary (1=Yes, 0=No)

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
61.13% 55.72% 39.79% 19.93% 19.93% 19.93% 19.93% 19.93% 19.93% 18.19% 18.19% 4.70%
38.86% 44.28% 60.21% 80.07% 80.07% 80.07% 80.07% 80.07% 80.08% 81.81% 81.79% 95.29%
No. of Shareholders 1,1561,1691,1851,2411,2421,6291,9252,3022,7212,8992,9263,065

Documents

Announcements

Annual reports